previously scientific research of CagriSema observed that it assisted clients accomplish substantially increased weight loss than semaglutide (Wegovy) did. regardless of whether Lilly's Zepbound/Mounjaro topples Wegovy, It is really attainable that CagriSema could enter the industry at the correct time for Novo Nordisk to retain its Over-all leader